Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
IPO ETF slides 8% amid market carnage ahead of expected Bausch + Lomb pricing
08:17pm, Thursday, 05'th May 2022 MarketWatch
The Renaissance IPO ETF tumbled 8% Thursday, swept up in the carnage in broader markets as major indexes more than wiped out the gains made Wednesday in a relief rally following a widely expected inte
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates
12:45pm, Thursday, 05'th May 2022 Zacks Investment Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch + Lomb IPO: What You Need to Know
12:10pm, Tuesday, 03'rd May 2022
Bausch + Lomb, a well-known leader in eye care, is about to hit Wall Street in what investment bankers almost certainly hope will jump-start a weak initial public offering (IPO) market. Bausch Health
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
09:50pm, Monday, 02'nd May 2022 Zacks Investment Research
Bausch Health (BHC) closed the most recent trading day at $18.85, moving -0.84% from the previous trading session.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
02:54pm, Monday, 02'nd May 2022 Zacks Investment Research
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?
02:40pm, Monday, 02'nd May 2022
Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. The post BLCO Stock IPO: When Does Bausch + Lomb Go Public?
IPO Report: U.S. IPO market bracing for second-biggest deal of the year so far in eyecare health company Bausch + Lomb
02:25pm, Monday, 02'nd May 2022
The U.S. initial public offering market is bracing for what is expected to be the second-biggest deal of the year so far this week, that of eyecare company Bausch & Lomb, which is expected to raise up
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
12:02pm, Monday, 02'nd May 2022
The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.
Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know
10:00pm, Monday, 25'th Apr 2022 Zacks Investment Research
Bausch Health (BHC) closed at $21.48 in the latest trading session, marking a -0.88% move from the prior day.
The Smartest Dividend Stocks to Buy With $400 Right Now
11:50am, Friday, 22'nd Apr 2022 The Motley Fool
Set yourself up to collect a little extra cash while waiting for the market to figure out where it wants to go next.
Revisiting Bausch: $7.5B Market Cap Too Low
10:09am, Wednesday, 20'th Apr 2022
Bausch Health Companies has lost 25% of its equity value so far this year. Management continues to execute on their strategic alternatives plan to drive shareholder value.
Aerie (AERI) Expands Market Presence Despite Stiff Competition
06:54pm, Monday, 11'th Apr 2022 Zacks Investment Research
Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
10:00pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
In the latest trading session, Bausch Health (BHC) closed at $23.23, marking a -1.69% move from the previous day.
Bausch Health (BHC) Stock Moves -0.56%: What You Should Know
10:00pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
In the latest trading session, Bausch Health (BHC) closed at $23.17, marking a -0.56% move from the previous day.
Bausch to reduce debt by another $200 million by repaying senior loans on March 31
08:09am, Tuesday, 29'th Mar 2022
Bausch Health Cos. Inc. BHC, -1.05% said Tuesday it will reduce its debt by $200 million by paying down senior loans on March 31 using cash generated from operations.
